Insider moves in IonQ, Hims and Hers, Eli Lilly, and TransMedics reveal bold buys, record sales, and signals worth watching.

Hims & Hers Health’s second quarter results were met with a significant negative market reaction, as sales growth lagged Wall Street’s expectations despite a strong rise in non-GAAP profitability.

In Q2 2025, Hims & Hers reported adjusted earnings of $0.17 per share, topping estimates of $0.15. Revenue rose 73% year-over ...

In separate filings, Chief Legal Officer Soleil Boughton sold 2,572 shares at a price of $51.64 apiece for $132,818, while ...

What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 3.6% in the afternoon session after the ...

Shares of Hims & Hers Health Inc. have roughly doubled over the past year — and Chief Executive Andrew Dudum cashed in on the ...

Hims & Hers Health ( NYSE: HIMS) shares traded lower for the second straight session on Tuesday after the telehealth firm’s ...

What Happened: According to a Form 4 filing with the U.S. Securities and Exchange Commission on Monday, Dudum sold 660,000 shares of Hims & Hers Health. The total transaction value is $33,384,120. The ...

Ten stocks mirrored a lackluster performance in the broader market on Tuesday, posting hefty double-digit losses primarily due to disappointing earnings performance and a lower growth outlook for the ...

Hims & Hers Health shares fell 12% in after-hours trading on Monday after the telehealth company missed second-quarter ...

Hims & Hers Health, Inc. HIMS stock is trading lower Tuesday after the company reported a second-quarter sales miss on Monday ...

Hims & Hers Health stock fell as much as 5% early Tuesday after the company reported revenue late Monday that fell shy of ...